Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Enrollment under way in Modrenal prostate cancer study

Sep. 28, 2004

Alimta approved in Europe for malignant pleural mesothelioma and NSCLC

Sep. 28, 2004

Sopherion licenses North American rights to Myocet

Sep. 28, 2004

New antitumor agents and their use in ALL therapy

Sep. 28, 2004

Pharmion's MAA for Vidaza accepted for review by EMEA

Sep. 27, 2004

Introgen Therapeutics receives NCI grant to further mda-7 gene research

Sep. 27, 2004

New antitumor, antibacterial and antifungal agents isolated from Streptomyces sp.

Sep. 27, 2004

Oxazepine-based antitumor agents newly discovered at Servier

Sep. 27, 2004

Tarceva plus gemcitabine combination improves survival in pancreatic cancer patients

Sep. 23, 2004

PD-332991 enters phase I

Sep. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...